Genetic Engineering Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Genetic Engineering stocks.

Genetic Engineering Stocks Recent News

Date Stock Title
Nov 20 PGEN Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86%
Nov 20 TWST Twist Bioscience Full Year 2024 Earnings: EPS Misses Expectations
Nov 20 TWST Twist Bioscience price target lowered to $52 from $55 at Barclays
Nov 20 EDIT Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)
Nov 19 TWST Twist Bioscience Corporation (TWST): Among the Best Genomics Stocks to Buy Right Now
Nov 19 TWST Company News for Nov 19, 2024
Nov 19 TWST Q4 2024 Twist Bioscience Corp Earnings Call
Nov 19 TWST Twist Bioscience Corp (TWST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
Nov 19 NGNE Neurogene GAAP EPS of -$1.19 in-line
Nov 18 NGNE Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
Nov 18 NGNE How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
Nov 18 TWST Twist Bioscience: A Post-Earnings Assessment
Nov 18 TWST Twist Bioscience rises 13% on FQ4 earnings beats, 2025 revenue outlook
Nov 18 TWST Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
Nov 18 MGX What Makes Metagenomi (MGX) a New Buy Stock
Nov 18 TWST Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript
Nov 18 NGNE Neurogene stock plunges 36% on NGN-401 study update
Nov 18 TWST Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Nov 18 TWST Earnings Snapshot: Twist Bioscience tops FQ4 estimates; initiates FQ1 and FY25 outlook
Nov 18 TWST Twist Bioscience: Fiscal Q4 Earnings Snapshot
Genetic Engineering

Genetic engineering, also called genetic modification or genetic manipulation, is the direct manipulation of an organism's genes using biotechnology. It is a set of technologies used to change the genetic makeup of cells, including the transfer of genes within and across species boundaries to produce improved or novel organisms. New DNA is obtained by either isolating and copying the genetic material of interest using recombinant DNA methods or by artificially synthesising the DNA. A construct is usually created and used to insert this DNA into the host organism. The first recombinant DNA molecule was made by Paul Berg in 1972 by combining DNA from the monkey virus SV40 with the lambda virus. As well as inserting genes, the process can be used to remove, or "knock out", genes. The new DNA can be inserted randomly, or targeted to a specific part of the genome.
An organism that is generated through genetic engineering is considered to be genetically modified (GM) and the resulting entity is a genetically modified organism (GMO). The first GMO was a bacterium generated by Herbert Boyer and Stanley Cohen in 1973. Rudolf Jaenisch created the first GM animal when he inserted foreign DNA into a mouse in 1974. The first company to focus on genetic engineering, Genentech, was founded in 1976 and started the production of human proteins. Genetically engineered human insulin was produced in 1978 and insulin-producing bacteria were commercialised in 1982. Genetically modified food has been sold since 1994, with the release of the Flavr Savr tomato. The Flavr Savr was engineered to have a longer shelf life, but most current GM crops are modified to increase resistance to insects and herbicides. GloFish, the first GMO designed as a pet, was sold in the United States in December 2003. In 2016 salmon modified with a growth hormone were sold.
Genetic engineering has been applied in numerous fields including research, medicine, industrial biotechnology and agriculture. In research GMOs are used to study gene function and expression through loss of function, gain of function, tracking and expression experiments. By knocking out genes responsible for certain conditions it is possible to create animal model organisms of human diseases. As well as producing hormones, vaccines and other drugs genetic engineering has the potential to cure genetic diseases through gene therapy. The same techniques that are used to produce drugs can also have industrial applications such as producing enzymes for laundry detergent, cheeses and other products.
The rise of commercialised genetically modified crops has provided economic benefit to farmers in many different countries, but has also been the source of most of the controversy surrounding the technology. This has been present since its early use; the first field trials were destroyed by anti-GM activists. Although there is a scientific consensus that currently available food derived from GM crops poses no greater risk to human health than conventional food, GM food safety is a leading concern with critics. Gene flow, impact on non-target organisms, control of the food supply and intellectual property rights have also been raised as potential issues. These concerns have led to the development of a regulatory framework, which started in 1975. It has led to an international treaty, the Cartagena Protocol on Biosafety, that was adopted in 2000. Individual countries have developed their own regulatory systems regarding GMOs, with the most marked differences occurring between the US and Europe.

Browse All Tags